Hepatitis Monthly

Published by: Kowsar

Baseline Prognostic Factors and Statistic Model to Predict Early Virological Response in Telbivudine-Treated Patients With Chronic Hepatitis B

Rui Zhou 1 , 2 , Yuan-Ping Zhou 1 , * , Chun Lin 2 , Hai-bing Gao 2 , Shui-wen Huang 2 , Zu-xiong Huang 2 , Fang Sun 2 , Yong Lin 2 , Dong-qing Zhang 2 , Qing-feng Lin 2 , Wen Ao 2 and Chen Pan 2 , *
Authors Information
1 Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China
2 Infectious Disease Hospital, Meng Chao Hepatobiliary Hospital, Fujian Medical University, Fuzhou, China
Corresponding Authors:
Article information
  • Hepatitis Monthly: December 01, 2013, 13 (12); e15573
  • Published Online: December 23, 2013
  • Article Type: Brief Report
  • Received: October 24, 2013
  • Revised: November 24, 2013
  • Accepted: November 30, 2013
  • DOI: 10.5812/hepatmon.15573

To Cite: Zhou R, Zhou Y, Lin C, Gao H, Huang S, et al. Baseline Prognostic Factors and Statistic Model to Predict Early Virological Response in Telbivudine-Treated Patients With Chronic Hepatitis B, Hepat Mon. 2013 ;13(12):e15573. doi: 10.5812/hepatmon.15573.

Abstract
Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet. 2003; 362(9401): 2089-94[DOI][PubMed]
  • 2. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006; 45(4): 529-38[DOI][PubMed]
  • 3. Hepatitis B Fact sheet WHO/204. 2000;
  • 4. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis. 2005; 25 Suppl 1: 3-8[DOI][PubMed]
  • 5. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut. 1991; 32(3): 294-8[PubMed]
  • 6. Ohata K, Hamasaki K, Toriyama K, Ishikawa H, Nakao K, Eguchi K. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol. 2004; 19(6): 670-5[DOI][PubMed]
  • 7. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006; 295(1): 65-73[DOI][PubMed]
  • 8. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol. 2006; 101(8): 1797-803[DOI][PubMed]
  • 9. Yuan HJ, Yuen MF, Ka-Ho Wong D, Sablon E, Lai CL. The relationship between HBV-DNA levels and cirrhosis-related complications in Chinese with chronic hepatitis B. J Viral Hepat. 2005; 12(4): 373-9[DOI][PubMed]
  • 10. Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005; 54(11): 1610-4[DOI][PubMed]
  • 11. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology. 2003; 37(6): 1309-19[DOI][PubMed]
  • 12. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004; 351(15): 1521-31[DOI][PubMed]
  • 13. Standring DN, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother. 2001; 12 Suppl 1: 119-29[PubMed]
  • 14. Lai CL, Lim SG, Brown NA, Zhou XJ, Lloyd DM, Lee YM, et al. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology. 2004; 40(3): 719-26[DOI][PubMed]
  • 15. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005; 129(2): 528-36[DOI][PubMed]
  • 16. Bridges EG. 388 Telbivudine preclinical safety studies suggest minimal risk of chronic toxicity, reproductive toxicity or carcinogenicity. J Hepatol. 2006; 44
  • 17. Deng M, Zhou X, Gao S, Yang SG, Wang B, Chen HZ, et al. The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis. Virol J. 2012; 9: 185[DOI][PubMed]
  • 18. Yuen MF, Sablon E, Hui CK, Yuan HJ, Decraemer H, Lai CL. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology. 2001; 34(4 Pt 1): 785-91[DOI][PubMed]
  • 19. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol. 2006; 44(2): 422-31[DOI][PubMed]
  • 20. Nguyen MH, Keeffe EB. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat. 2009; 16(3): 149-55[DOI][PubMed]
  • 21. Tillmann HL, McHutchison JG. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2008; 358(14): 1517[DOI][PubMed]
  • 22. Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009; 136(2): 486-95[DOI][PubMed]
  • 23. Yuen MF, Sablon E, Libbrecht E, Van De Velde H, Wong DK, Fung J, et al. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment. Antivir Ther. 2006; 11(6): 779-86[PubMed]
  • 24. Yuen MF, Fong DY, Wong DK, Yuen JC, Fung J, Lai CL. Hepatitis B virus DNA levels at week 4 of lamivudine treatment predict the 5-year ideal response. Hepatology. 2007; 46(6): 1695-703[DOI][PubMed]
  • 25. Cox DR. Regression models and life-tables. J R Stat Soc. 1972; 34: 187-220
  • 26. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology. 1989; 10(5): 761-3[PubMed]
  • 27. Marinos G, Naoumov NV, Williams R. Impact of complete inhibition of viral replication on the cellular immune response in chronic hepatitis B virus infection. Hepatology. 1996; 24(5): 991-5[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments